Cargando…

Prediction of residual ischemic risk in ticagrelor-treated patients with acute coronary syndrome

BACKGROUND: Despite strong antiplatelet therapy with ticagrelor, serious ischemic events still occur in patients with acute coronary syndrome (ACS). The predictability of platelet reactivity to the residual risk of ischemic events during ticagrelor treatment remains uncertain. OBJECTIVES: We aimed t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zou, Yuting, Wang, Yuyan, Wu, Yangxun, Zhang, Shizhao, Liu, Haiping, Yin, Tong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022318/ https://www.ncbi.nlm.nih.gov/pubmed/35448998 http://dx.doi.org/10.1186/s12959-022-00380-4

Ejemplares similares

Efficacy and Safety of Antithrombotic Therapy With Oral Anticoagulants in Real-World Elderly Patients With Acute Coronary Syndrome and Atrial Fibrillation
por: Wu, Yangxun, et al.
Publicado: (2022)

Efficacy and safety of oral anticoagulants in elderly patients with stable coronary artery disease and atrial fibrillation
por: Zhang, Xu, et al.
Publicado: (2022)

Incremental Value of Genotype Bins over the HAS-BLED Score for the Prediction of Bleeding Risk in Warfarin-Treated Patients with Atrial Fibrillation
por: Liu, Jia, et al.
Publicado: (2021)

Dyspnoea management in acute coronary syndrome patients treated with ticagrelor
por: Parodi, Guido, et al.
Publicado: (2015)

Metabolism of ticagrelor in patients with acute coronary syndromes
por: Adamski, Piotr, et al.
Publicado: (2018)

Determinants of high platelet reactivity in patients with acute coronary syndromes treated with ticagrelor
por: Adamski, Piotr, et al.
Publicado: (2019)

Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor
por: Birkeland, Kade, et al.
Publicado: (2010)

Critical appraisal of ticagrelor in the management of acute coronary syndrome
por: Nawarskas, James J, et al.
Publicado: (2011)

Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis
por: Wang, Dong, et al.
Publicado: (2018)

“Real‐World” Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States
por: Larmore, Cynthia, et al.
Publicado: (2015)

Comparison of ticagrelor with clopidogrel on quality of life in patients with acute coronary syndrome
por: Moon, Hyeyeon, et al.
Publicado: (2021)

Hospital‐Level Variation in Ticagrelor Use in Patients With Acute Coronary Syndrome
por: Ozaki, Aya F., et al.
Publicado: (2022)

Effect of altitude on ticagrelor-induced dyspnea in patients with acute coronary syndrome
por: Kocabay, Gonenc, et al.
Publicado: (2023)

Oral NAloxone to overcome the moRphine effect in acute COronary syndrome patients treated with TICagrelor — NARCOTIC trial
por: Niezgoda, Piotr, et al.
Publicado: (2022)

Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2‐Hour Infusion in High‐Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention
por: Marian, Moazez J., et al.
Publicado: (2017)

Cost-effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes in Canada
por: Grima, Daniel T, et al.
Publicado: (2014)

Long-term cost effectiveness of ticagrelor in patients with acute coronary syndromes in Thailand
por: Yamwong, Sukit, et al.
Publicado: (2014)

Effects of switching ticagrelor to clopidogrel on cardiovascular outcomes in patients with acute coronary syndrome
por: Liu, Lin, et al.
Publicado: (2018)

Ticagrelor after Acute Coronary Syndrome: One For All or Part of Personalized Medicine?
por: Akin, Ibrahim, et al.
Publicado: (2022)

Cost-Effectiveness Comparison between Ticagrelor and Clopidogrel in Acute Coronary Syndrome in Iran
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2023)

Clinical effect of ticagrelor administered in acute coronary syndrome patients following percutaneous coronary intervention
por: LU, YANJIAO, et al.
Publicado: (2016)

Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack
por: Wang, Yongjun, et al.
Publicado: (2022)

Ticagrelor-induced Diarrhea in a Patient with Acute Coronary Syndrome Requiring Percutaneous Coronary Artery Intervention
por: Alomari, Mohammad, et al.
Publicado: (2019)

Economic Evaluation of Ticagrelor Plus Aspirin Versus Aspirin Alone for Acute Ischemic Stroke and Transient Ischemic Attack
por: Chen, Jigang, et al.
Publicado: (2022)

Effects of switching ticagrelor to clopidogrel on cardiovascular outcomes in patients with acute coronary syndrome: Erratum
Publicado: (2018)

Comparison of atrial fibrillation predictors in patients with acute coronary syndrome using ticagrelor or clopidogrel
por: ALGÜL, Engin, et al.
Publicado: (2019)

Clinical Outcome between Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndrome and Diabetes
por: He, Peixun, et al.
Publicado: (2021)

Combined glycoprotein IIb/IIIa inhibitor therapy with ticagrelor for patients with acute coronary syndrome
por: Xie, Zhi-Jiang, et al.
Publicado: (2021)

Influence of body size on platelet response to ticagrelor and prasugrel in patients with acute coronary syndromes
por: Ndrepepa, Gjin, et al.
Publicado: (2021)

Ticagrelor Versus Clopidogrel in East Asian Patients With Acute Coronary Syndrome and Diabetes Mellitus
por: Choi, Yeonwoo, et al.
Publicado: (2022)

Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndrome and on Dialysis: A Meta-Analysis
por: Chenna, Venkata Sai Harshabhargav, et al.
Publicado: (2023)

Ischemic Benefit and Hemorrhage Risk of Ticagrelor-Aspirin Versus Aspirin in Patients With Acute Ischemic Stroke or Transient Ischemic Attack
por: Johnston, S. Claiborne, et al.
Publicado: (2021)

Optimal strategy of switching from clopidogrel to ticagrelor in Chinese acute coronary syndrome patients with complicated coronary artery disease: the switching from clopidogrel to ticagrelor (SHIFT-CACS) study
por: Yao, Ying, et al.
Publicado: (2019)

Comparison of Ticagrelor Monotherapy and Ticagrelor Plus Aspirin Among Patients With Acute Coronary Syndrome Combined With High-Risk of Gastrointestinal Bleeding After Percutaneous Coronary Intervention: A Retrospective Cohort Study
por: Tian, Ming-Yu, et al.
Publicado: (2023)

Ticagrelor Resistance in Cardiovascular Disease and Ischemic Stroke
por: He, Song, et al.
Publicado: (2023)

Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin
por: Amarenco, Pierre, et al.
Publicado: (2020)

Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy
por: Janzon, M, et al.
Publicado: (2015)

Efficacy and safety outcomes of ticagrelor compared with clopidogrel in elderly Chinese patients with acute coronary syndrome
por: Wang, Huidong, et al.
Publicado: (2016)

Impact of Prasugrel and Ticagrelor on Platelet Reactivity in Patients With Acute Coronary Syndrome: A Meta-Analysis
por: Dai, Lulu, et al.
Publicado: (2022)

Ticagrelor versus Clopidogrel in Patients with Severe Renal Insufficiency Undergoing PCI for Acute Coronary Syndrome
por: Chen, Yunxian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dh7hjr10g6cekaia2b9mv2jov7